Abstract
This review will summarize the major efforts currently underway to develop osteoinductive bone graft substitutes for minimally invasive spine fusions. The primary categories of substitute include purified bone growth factors, recombinant bone growth factors, and growth factors delivered by gene therapy approaches. Clinical trials are underway for the purified and recombinant bone growth factors and pre-clinical studies have yielded promising results for a variety of gene therapy techniques for generating bone.
Keywords: Key words Bone morphogenetic ¶protein, Gene therapy, Bone graft ¶substitute, Spine fusion
Full Text
The Full Text of this article is available as a PDF (42.7 KB).
Footnotes
Received: 4 August 1999 /Accepted: 26 August 1999